Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in ad
Go back to Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in ad| AbbVie (NYSE: ABBV) | Delayed: 248.78 -7.68 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $256.46 | 52 Week High | $68.12 | |||
| Open | $251.84 | 52 Week Low | $50.71 | |||
| Day High | $254.62 | P/E | 53.97 | |||
| Day Low | $248.41 | EPS | $4.61 | |||
| Volume | 5,115,635 | |||||
